Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Showing 1 - 20 of 20

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor Trial (INX-315)

Not yet recruiting
  • Breast Cancer
  • +8 more
  • (no location specified)
Feb 9, 2023

Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Boston (Eribulin, Adriamycin,

Active, not recruiting
  • Inflammatory Breast Cancer
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • Boston, Massachusetts
  • +1 more
Nov 28, 2022

Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Bronx (Rebastinib,

Terminated
  • Breast Cancer
  • +4 more
  • Bronx, New York
    Montefiore Medical Center
Mar 23, 2022

Breast Cancer, Estrogen Receptor Positive Breast Cancer, Node-negative Breast Cancer Trial in Boston (Breast Cancer Treatment

Completed
  • Breast Cancer
  • +3 more
  • Breast Cancer Treatment Decision Aid for women 70+
  • Usual Care
  • Boston, Massachusetts
  • +1 more
Mar 10, 2022

Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Washington, District of Columbia
    Lombardi Comprehensive Cancer Center
Jan 17, 2022

Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Germany

Active, not recruiting
  • Breast Cancer
  • +2 more
  • Aachen, Germany
  • +69 more
Dec 1, 2021

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer Trial in Amsterdam (Paclitaxel,

Completed
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • Metastatic Breast Cancer
  • Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
  • Amsterdam, Netherlands
    BOOG Study Center
Jan 16, 2020

Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Early-Stage Breast Carcinoma Trial in Fuenlabrada,

Completed
  • Breast Cancer
  • +2 more
  • Fuenlabrada, Madrid, Spain
  • +4 more
Jul 22, 2019

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial (Oral NVB Metronomic, Oral NVB Weekly)

Not yet recruiting
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • Oral NVB Metronomic
  • Oral NVB Weekly
  • (no location specified)
Feb 23, 2019

Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer Trial

Terminated
  • Estrogen Receptor-positive Breast Cancer
  • +6 more
  • Tucson, Arizona
    Arizona Cancer Center
Jul 23, 2018

Radiotherapy Alternates Human Epidermal Growth Factor 2

Suspended
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    • Qingdao, Shandong, China
      Qingdao Central Hospital, Qingdao Cancer Hospital
    Feb 13, 2018

    Patterns of Prescribing and Monitoring of Palbociclib

    Completed
    • Metastatic Breast Cancer
    • +3 more
    • (no location specified)
    Oct 24, 2017

    Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast

    Terminated
    • Estrogen Receptor Negative Breast Cancer
    • +5 more
    • Birmingham, Alabama
    • +15 more
    May 22, 2017

    Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Italy (Bevacizumab and eribulin)

    Unknown status
    • Metastatic Breast Cancer
    • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    • Bevacizumab and eribulin
    • Cremona, Italy
    • +16 more
    Jun 14, 2016

    Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Tumor Trial in Italy (Everolimus, Exemestane, Fulvestrant)

    Unknown status
    • Metastatic Breast Cancer
    • +4 more
    • Asti, Italy
    • +40 more
    Jun 14, 2016

    Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer Trial in Tucson (drug,

    Completed
    • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    • +4 more
    • Tucson, Arizona
      Arizona Cancer Center
    Apr 20, 2016

    Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Italy (Metformin + Myocet + Cyclophosphamide, Myocet +

    Completed
    • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    • Metformin + Myocet + Cyclophosphamide
    • Myocet + Cyclophosphamide
    • Cesena, FC, Italy
    • +24 more
    Dec 31, 2015

    XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B

    Unknown status
    • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
      • Guangzhou, Guangdong, China
        Guangdong Academy of Medical Sciences
      Jan 28, 2013